Europe lacks effective policies to support return to work by breast cancer survivors.

More women are surviving breast cancer, but return to work rates vary considerably across Europe.

Employers' actions and attitudes are central to successful return to work by survivors.

WiB BC Cut InfographicAlthough the rate of breast cancer diagnoses is rising in Europe, a higher proportion of women are surviving the form of cancer - but returning to everyday aspects of life prove challenging; with many survivors unable to return to work, due to a lack of support and consideration by employers. A new report by The Economist Intelligence Unit and commissioned by Pfizer, investigates the challenges involved in returning to employment for a growing number of breast cancer patients and survivors of a working age.

There is substantial variation in national return-to-work rates across European Union countries.

  • Britain had Europe's, as well as the world's, fifth-highest crude breast cancer incidence rate in 2012, at 164.5 per 100,000 women.
  • As a result, the UK has a substantial five-year prevalence of breast cancer patients and survivors in the population (755.1 per 100,000), or just over 200,000 women.
  • In 2008, the total number of breast cancer patients and survivors in the country was about three times that of those diagnosed only within the last five years.

This suggests room for improvement in policies and practices to support those who wish to return to work.

Because the feeling of not being able to work and isolation can be devastating for most patients and survivors, re-entering employment is crucial to returning back to normality and getting their life back. However not all who wish to return to work succeed, the side effects of breast cancer and treatment make returning to work harder, but these are far from the only issues.

Important non-medical barriers also impede return to work, including:

  • Lack of employer or colleague support
  • The extent to which work is physically demanding
  • Socio-demographic including level of education, marital status, financial dependence

Such factors overlap to make particular populations vulnerable, especially working class women. To date, these challenges are often overlooked by stakeholders who could act in important ways to ease returning to work.

Key stakeholders include:

Clinicians: Healthcare professionals are frequently unaware of the issues around employment and breast cancer, or uncomfortable talking about them. As working has become a realistic possibility for patients and survivors, doctors and nurses should begin to discuss these questions with their patients as part of a growing focus on the challenges and opportunities of survivorship.

Employers: Most employers have also not begun to address how to deal with employees who develop cancer. Rather than waiting for someone to become ill, and responding in an ad hoc way, they should think ahead in order to have appropriate policies and, where appropriate, programmes in place. These should emphasise communication with an eye to shaping responses tailored to individual situations.

Governments: Legislation and policy shaping the environment for return to work of chronic breast cancer patients and survivors either – in many European countries – is completely lacking or was designed with other needs in mind. Policy makers therefore should also engage with the issue, retrofitting relevant disability and return to work legislation or putting effective policies in place. NCCPs also should, as part of an increasing focus on survivorship, include employment issues.

"While data on the likely impact of specific interventions are sparse, this study finds that simply engaging with the return-to-work issue is an important first step to ensure that breast cancer survivors receive the support they need," said Aviva Freudmann, research director – EMEA Thought Leadership for the Economist Intelligence Unit, who directed the study.

"Due to meaningful advancements in the detection and treatment of breast cancer, an increasing number of women are living with or surviving the disease," said Andreas Penk, M.D., regional president, International Developed Markets, Pfizer Oncology. "With this progress comes new challenges for these women as they strive to return to their normal lives, which may include working. The results of this research suggest an urgent need for alignment from employers, governments and healthcare providers to support breast cancer survivors as they rejoin the workforce."

Press enquiries:

Matt Anderson, Account Manager, TVC
This email address is being protected from spambots. You need JavaScript enabled to view it. 

Notes to editors

About The Economist Intelligence Unit

We deliver vital business intelligence to executives the world over. With access to over 650 expert analysts and editors across 200 countries worldwide, underpinned by an unrivalled in-house survey panel that bolsters the qualitative and quantitative analysis, we uncover novel and forward-looking perspectives. We apply the same rigor of our editorial heritage to design content that goes beyond the expected. And our reputation for authority and independence ensures access to elite contributors in every market in the world, providing truly distinctive viewpoints. More information can be found at or

About Pfizer Oncology

Pfizer Oncology is committed to pursuing innovative treatments that have a meaningful impact on those living with cancer. As a leader in oncology speeding cures and accessible breakthrough medicines to patients, Pfizer Oncology is helping to redefine life with cancer. Our strong pipeline of biologics, small molecules and immunotherapies, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments and licensing partners, Pfizer Oncology strives to cure or control cancer with its breakthrough medicines. Because Pfizer Oncology knows that success in oncology is not measured solely by the medicines you manufacture, but rather by the meaningful partnerships you make to have a more positive impact on people's lives. Learn more about how Pfizer Oncology is applying innovative approaches to improve the outlook for people living with cancer at 

Our Breast Cancer Vision: Transcending Boundaries, Transforming Care

Pfizer Oncology is deeply committed to advancing scientific innovation and transforming the current state of breast cancer care for the millions of women around the world who face its challenges every day. Through Breast Cancer Vision, Pfizer is helping to change the future of breast cancer as we innovate through scientific endeavors that aim to improve outcomes, educate to enhance knowledge of evolving patient needs, and activate the global community to develop solutions that improve patient care. For more information, visit